A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer

Kim, TY; Han, HS; Lee, KW; Zang, DY; Rha, SY; Park, YL; Kim, JS; Lee, KH; Park, SH; Song, EK; Jung, SA; Lee, N; Kim, YH; Cho, JY; Bang, YJ

Bang, YJ (reprint author), Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Internal Med, 101 Daehak Ro, Seoul 03080, South Korea.

GASTRIC CANCER, 2019; 22 (6): 1206

Abstract

Background Poziotinib (HM781-36B) is an irreversible pan-HER tyrosine kinase inhibitor which targets EGFR, HER2, and HER4. This prospective, multicent......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索